NovellusDx brings actionable information about the mutations found in patients’ tumor and the response of these mutations to targeted therapies. NovellusDx tests the functional significance of the specific mutations and their interactions in live cells examining how they change the activity level of major cancer signaling pathways and how this is affected by different targeted therapies. The next-generation sequencing-based FACT assay is designed to test the functional effects of variants of unknown significance in reponse to various cancer treatments to predict clinical results.
Under the terms of the deal, Tokyo-based Primetech will be the exclusive dealer for the assay for the preclinical market in Japan, providing all related sales, marketing, research, and technical support in the region.
Earlier this year, Jerusalem-based NovellusDx partnered with Centre Léon-Bérard to evaluate the accuracy of the FACT assay in predicting treatment responses in cancer patients. The company also recently raised $6 million in equity financing.
NovellusDx’s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDx’s headquarters and research and development operations are based in Jerusalem, Israel.